Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Panel Discussion
Manage episode 354948767 series 3381434
Thông tin tác giả ReachMD được phát hiện bởi Player FM và cộng đồng của chúng tôi - bản quyền thuộc sở hữu của nhà sản xuất (publisher), không thuộc về Player FM, và audio được phát trực tiếp từ máy chủ của họ. Bạn chỉ cần nhấn nút Theo dõi (Subscribe) để nhận thông tin cập nhật từ Player FM, hoặc dán URL feed vào các ứng dụng podcast khác.
CME credits: 0.50
Valid until: 07-02-2024
Claim your CME credit at https://reachmd.com/programs/cme/paradigm-shifts-in-car-t-cell-therapy-for-relapsedrefractory-large-b-cell-lymphoma/14589/
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now three approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
…
continue reading
Valid until: 07-02-2024
Claim your CME credit at https://reachmd.com/programs/cme/paradigm-shifts-in-car-t-cell-therapy-for-relapsedrefractory-large-b-cell-lymphoma/14589/
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now three approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features an expert roundtable panel discussion on real-world clinical practice experiences with CAR T-cell therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) from the esteemed panelists, with a focus on the second-line setting. The faculty panel will evaluate the most recent clinical data and provide their expert insights on how new emerging evidence can and should be considered for real-world clinical practice. The discussion will also include a summary of second-line clinical trials, differentiation factors among …=
983 tập
Chia sẻ
))
